Clinical Trials Browser

Phase 2 × Uterine Cervical Neoplasms × Immune Checkpoint Inhibitors × Clear all

NCT06455072 2024-06-12

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT05588219 2023-11-24

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Phase 2 Unknown

Uterine Cervical Neoplasms